Trafermin

Summary

Trafermin (CHEMBL2108081) is an approved protein (ATC D03AX15); indicated across 4 conditions including periodontitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: D03AX15
• Indications: 4 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108081
Name	Trafermin
Type	Protein
Max phase	4
ATC	D03AX15

Also known as: CAB-2001, Fiblast, RHBFGF, Trafermin, Trafermina, Trafermine, TRAFERMIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
periodontitis	3	MONDO:0005076	EFO:0000649

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01015404	PHASE3	COMPLETED	A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)
NCT01217463	PHASE3	COMPLETED	The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study
NCT01217476	PHASE3	COMPLETED	The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study
NCT02550314	PHASE3	COMPLETED	A Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).